BioSpace News Archive

Orexo AB, announces positive results from the first explorative human clinical study for its nasal epinephrine rescue medication for allergic reactions, OX640.

Precision BioSciences, Inc. announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre.

Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health.

SeaSpine Holdings Corporation announced preliminary financial results for the third quarter of 2022.

Orthofix Medical Inc. announced preliminary unaudited third quarter 2022 net sales of approximately $114 million, an increase of 1% on a reported basis and 5% on a constant currency basis versus the prior year.

Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, announced the close of a $112 million Series B financing.

Arch Therapeutics, Inc. announced that two abstracts highlighting the role of the Company’s AC5® Advanced Wound System in clinical cases were accepted for Poster Presentations at the upcoming 2022 Symposium on Advanced Wound Care Fall—with one receiving the honor for “Highest Scoring Poster Abstract in Case Series/Study Category”—a distinction awarded by a panel of expert judges during a blind-review.

Bio-Techne Corporation and PROGEN announced the release of three new Simple Plex™ Adeno-Associated Virus viral titer assays for intact AAV capsid quantification.

Ginkgo Bioworks today announced a collaboration with Merck to engineer up to four enzymes for use as biocatalysts in Merck’s active pharmaceutical ingredient (API) manufacturing efforts.

Metagenomi announced that it has opened a new, in-house Good Manufacturing Practices facility, based within its 50,000 square foot campus in Emeryville, California.